Light Emitting Diode-Red Light Phototherapy for Skin Fibrosis

项目摘要/摘要 皮肤纤维化，也被称为皮肤疤痕，是一个严重的医学问题，没有好的治疗选择。 皮肤纤维化是各种疾病的一个特征，从手术后的疤痕到创伤性损伤和烧伤， 免疫介导性疾病，包括硬皮病和慢性移植物抗宿主病。这些功能 统一的病理结果：成纤维细胞和胶原的增加导致皮肤增厚 导致严重的功能、社会和心理障碍。发光二极管红灯的使用 (LED-RL)是一种创新的方法，因为目前皮肤纤维化的治疗选择有限，而且 表现出不良的副作用，这是我们希望通过LED-RL光疗避免的。这是一项新的 使用LED-RL光疗的方法有可能将皮肤纤维化的治疗范式转变为 更安全、更便宜、便携、基于家庭的治疗。该方案的具体假设是LED-RL 光疗可通过减少体内真皮成纤维细胞改变手术后瘢痕形成的临床表现 数量和胶原，并基于体外初步数据，证明LED-RL具有抗纤维化作用 在较高剂量下，减少成纤维细胞的增殖和胶原蛋白。为了最终患者的利益，这种以患者为中心的 研究第一阶段和第二阶段临床试验旨在评估更高剂量的可见LED-RL的安全性，以及 确定LED-RL是否可用于减少手术后皮肤疤痕。我们还将筛选 基于RNA-Seq和microRNA的LED-RL光疗潜在的新型候选分子 并使用RT-PCR确认结果。我们的长期目标是开创新的LED-RL技术，使其成为更安全的 皮肤纤维化的治疗干预。在未来，我们希望研究这种方法的有效性。 LED-RL用于抑制或治疗烧伤、创伤和免疫介导的皮肤疤痕形成患者的疤痕形成。

PROJECT SUMMARY/ABSTRACT Skin fibrosis, also termed skin scarring, is a significant medical problem without good treatment options. Skin fibrosis is a feature of various diseases, ranging from post-surgical scarring to traumatic injury and burns, to immune-mediated conditions including scleroderma and chronic graft versus host disease. These feature unifying pathologic findings: an increased number of fibroblasts and collagen resulting in thickened skin that results in significant functional, social and psychological morbidity. The use of light emitting diode-red light (LED-RL) is an innovative approach, as current therapeutic options for skin fibrosis are limited and demonstrate undesirable side effects, something we hope to avoid with LED-RL phototherapy. This new approach using LED-RL phototherapy has the potential to shift the treatment paradigm for skin fibrosis toward safer, less expensive, portable, home-based therapy. The specific hypothesis of this proposal is that LED-RL phototherapy can alter the clinical manifestations of surgical scarring by reduction of in vivo dermal fibroblast number and collagen, and is based upon in vitro preliminary data that demonstrates that LED-RL is anti-fibrotic at higher doses, reducing fibroblast proliferation and collagen. For ultimate patient benefit, this patient-oriented research Phase I and Phase II clinical trials aim to evaluate the safety of higher doses of visible LED-RL, and determine whether LED-RL can be used to reduce skin scarring after surgery. We will also screen for potentially novel molecular candidates modulated by LED-RL phototherapy using RNA-Seq and microRNA arrays and confirm findings using RT-PCR. Our long-term goal is to pioneer new LED-RL technology as a safer therapeutic intervention for the treatment of skin fibrosis. In the future, we hope to study the effectiveness of LED-RL to inhibit or treat scarring in patients with burns, trauma, and immune-mediated forms of skin scarring.